Phaseline

Companies › Gossamer Bio USA

Gossamer Bio USA: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Seralutinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor
KIT, PDGFRB, PDGFRA, CSF1RPhase 3Pulmonary Arterial HypertensionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04816604SeralutinibPhase 2Pulmonary Arterial HypertensionCardiovascularSep 2026
NCT06274801SeralutinibPhase 3Pulmonary Arterial HypertensionCardiovascularDec 2026

From the company's SEC filings

Cash and short-term investments of $57m on 2026-06-30; operating cash outflow about $158m a year; runway about 4 months at that burn, to Nov 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

KIT (1) PDGFRB (1) PDGFRA (1) CSF1R (1)

Companies with the same targets

Daiichi Sankyo Deciphera Pharmaceuticals Blueprint Medicines Chia Tai Tianqing Pharmaceutical Group Novartis AstraZeneca Jiangsu HengRui Medicine AB Science Exelixis Ono Pharmaceutical

Companies built like this

Mineralys Therapeutics Grace Therapeutics Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.